Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/010912ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2
WO 13.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/040533 Applicant FLAGSHIP PIONEERING INNOVATIONS VI, LLC Inventor GRIGORYAN, Gevorg
The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g.,COVID-19).
2.WO/2022/010921ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2
WO 13.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/040546 Applicant FLAGSHIP PIONEERING INNOVATIONS VI, LLC Inventor GRIGORYAN, Gevorg
The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).
3.WO/2022/010353METHODS FOR IDENTIFYING CORONAVIRUS CROSS-REACTING ANTIBODIES
WO 13.01.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/NL2021/050435 Applicant LEYDEN LABORATORIES B.V. Inventor GOUDSMIT, Jaap
The disclosure provides methods for identifying coronavirus cross-reacting antibodies. Such antibodies bind to at least part of the S2 ectodomain of the S protein of at least one common human coronavirus selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1 and bind to at least part of the S2 ectodomain of the S protein of at least one highly pathogenic human coronavirus selected from SARS-CoV- 1, MERS-CoV and SARS-CoV-2. Antibodies identified by the methods described herein are particularly useful for treating or preventing coronaviral infections, in particular against highly pathogenic coronaviruses such as SARS-CoV-1, MERS-CoV and/or SARS-CoV-2 as well as cross-species transmission of typically non-human coronaviruses.
4.WO/2022/010955METHODS OF TREATING COVID-19 PATHOGENESIS
WO 13.01.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/US2021/040593 Applicant UT-BATTELLE, LLC Inventor JACOBSON, Daniel A.
This disclosure provides methods for treating a SARS-CoV-2 infection in a subject comprising administering to the subject an effective amount of an inhibitor of COVIDinduced RAS imbalance, that downregulates, for example, the Bradykinin system, the Renin-Angiotensin system, the hyaluronan synthesis pathway, or the fibrinogenesis pathway.
5.WO/2022/011110COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SARS-COV-2 VIRUS INFECTION
WO 13.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/040836 Applicant GEORGIA TECH RESEARCH CORPORATION Inventor FINN, M.G.
Compositions that selectively bind to coronaviruses, including but not limited to SARS-COV-2 and methods of use thereof are provided. The disclosed antibodies and antigen-binding fragments were developed against SARS-CoV-2. The antibodies bind to the spike protein of coronaviruses. The disclosed antibodies are useful for diagnosing, detecting, preventing, and treating coronavirus infections.
6.WO/2022/007304IGA ANTIBODY SPECIFICALLY RECOGNIZING RBD PROTEIN AND TESTING KIT
WO 13.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2020/130496 Applicant SHENZHEN YHLO BIOTECH CO., LTD Inventor CHENG, Fangming
The present invention relates to the technical field of virus testing. Provided is an IgA antibody capable of specifically recognizing an RBD protein. Said antibody is applied as a calibrator of the IgA antibody of the RBD protein of SARS-CoV-2. Also provided is a testing kit including said antibody. The testing kit achieves the automatic, high-throughput, and rapid testing of IgA antibodies of SARS-CoV-2.
7.WO/2022/011264DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ROTAVIRUS
WO 13.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/041094 Applicant THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY Inventor PARZYCH, Liz
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Rotavirus viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Rotavirus virus infection in a subject using said composition and method of generation.
8.WO/2022/006357RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND ANTIBODY FC REGION AND USES THEREOF
WO 06.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/040019 Applicant BOOST BIOPHARMA, INC. Inventor SCHOMBURG, Fritz M.
Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein and an antibody Fc region. Also provided are a method for preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by a beta coronavirus in a subject which includes administering to the subject the recombinant polypeptide, and a method for inducing an immune response against a beta coronavirus in a subject, which includes administering to the subject the recombinant polypeptide.
9.20220001006VIRUS LIKE NANOPARTICLE COMPOSITIONS AND METHODS THEREOF
US 06.01.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17361486 Applicant Regents of the University of Minnesota Inventor Frank Jonathan Lee

The present disclosure provides virus like nanoparticles (VLPs), which are capable of displaying multiple copies of a SARS-CoV-2 antigen, for eliciting protective immunity against a SARS-CoV-2 infection, as well as polypeptides, compositions and methods thereof.

10.WO/2022/006601HUMAN RECOMBINANT ACE2-FC MUTANTS THAT DECOUPLE ANTI-SARS-COV-2 ACTIVITY FROM CARDIOVASCULAR EFFECTS
WO 06.01.2022
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/US2021/070820 Applicant NORTHWESTERN UNIVERSITY Inventor JIN, Jing
Disclosed are compounds, compositions, and methods for treating and/or preventing infection by viruses that utilize the angiotensin converting enzyme 2 (ACE2) as a cellular receptor such as sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Particularly disclosed are recombinant ACE2-Fc fusion proteins and ACE2 variants that exhibit anti-SARS-CoV-2 binding activity and decouple anti-SARS-CoV-2 activity from side effects such as cardiovascular effects, where the fusion proteins and variants exhibit reduced ACE2 enzymatic activity.